The United States, once the largest supporter of HIV prevention globally, is facing significant funding cuts that jeopardize both domestic and international efforts to control HIV infections. Experts warn these decreases could undermine advancements made with lenacapavir, termed a 'miracle' drug due to its effectiveness in preventing HIV, which has recently gained FDA approval. Despite lenacapavir's potential to protect against HIV for up to six months, diminished resources for public health agencies could stymie the drug's distribution and detract from broader goals to end the epidemic by 2030.
Experts caution that funding cuts to both domestic and international health initiatives threaten the progress made in controlling HIV infections effectively.
Lenacapavir, viewed as a 'miracle' drug, offers a promising land-mark in the fight against HIV, but its benefits could be jeopardized by funding declines.
The approval of lenacapavir signifies a breakthrough, yet the looming cuts in public health funding could hinder its accessibility to those most in need.
The battle against HIV in the US is threatened by significant funding cuts, which may derail efforts to end the HIV epidemic by 2030.
Collection
[
|
...
]